SpringerLink
Log in

Brivaracetam – eine gute Alternative zur Behandlung von Muskelkrämpfen

Brivaracetam—A good alternative for the treatment of muscle cramps

  • Originalien
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Muskelkrämpfe sind plötzlich auftretende, unwillkürliche, meist schmerzhafte Kontraktionen eines Muskels, selten einer Muskelgruppe. Sie können idiopathisch oder im Rahmen unterschiedlicher neuromuskulärer Erkrankungen vorkommen und teilweise aufgrund ihrer Frequenz und Dauer die Lebensqualität erheblich beeinträchtigen. Zur Behandlung gibt es bislang nur wenige gut wirksame Medikamente.

Ergebnisse

In dieser Fallserie berichten wir von 5 Patienten mit Muskelkrämpfen unterschiedlicher Genese, die gut auf die Behandlung mit Brivaracetam ansprachen.

Diskussion

Brivaracetam wird eigentlich zur Behandlung epileptischer Anfälle eingesetzt. Es bindet an das synaptische Vesikelprotein 2A (SV2A), welches auch an Nerven- und Nervenwurzeln vorkommt. SV2A reguliert die exozytotische Freisetzung von Neurotransmittern, was die Wirkung von Brivaracetam auf Muskelkrämpfe erklären könnte.

Schlussfolgerung

Es sind weitere Studien erforderlich, um die Wirkung von Brivaracetam auf Muskelkrämpfe nachzuweisen.

Abstract

Background

Muscle cramps are suddenly occurring involuntary, mostly painful contractions of a single muscle, rarely of a muscle group. They can be idiopathic or occur in various neuromuscular diseases and can sometimes substantially impair the quality of life due to the frequency and strength. Only a few drugs are available for the effective treatment of cramps.

Results

In this case series we report on five patients with cramps of different origin who responded well to treatment with brivaracetam.

Discussion

Brivaracetam is actually used for the treatment of epileptic seizures. It binds to the synaptic vesicle protein 2A (SV2A), which also occurs in nerves and nerve roots. The SV2A regulates the exocytotic release of neurotransmitters, which could explain the effect of brivaracetam on muscle cramps.

Conclusion

Further studies are needed to demonstrate the effect of brivaracetam on muscle cramps.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abdulla AJ, Jones P, Pearce V (1999) Leg cramps in the elderly: prevalence, drug and disease associations. Int J Clin Pract 53:494–496

    CAS  PubMed  Google Scholar 

  2. Oboler SK, Prochazka AV, Meyer TJ (1991) Leg symptoms in outpatient veterans. West J Med 155:256–259

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Layzer RB (1994) The origin of muscle fasciculations and cramps. Muscle Nerve 17:1243–1249

    Article  CAS  Google Scholar 

  4. Miller TM, Layzer RB (2005) Muscle cramps. Muscle Nerve 32:431–442

    Article  Google Scholar 

  5. Schwellnus MP (2007) Muscle cram** in the marathon: aetiology and risk factors. Sports Med 37:364–367

    Article  Google Scholar 

  6. Salvatore CA (1961) Leg cramp syndrome in pregnancy. Obstet Gynecol 17:634–639

    CAS  PubMed  Google Scholar 

  7. Kiernan MC, Hart KI, Bostock H (2001) Excitability properties of motor axons in patients with spontaneous motor unit activity. J Neurol Neurosurg Psychiatry 70(1):56–64

    Article  CAS  Google Scholar 

  8. Parisi L, Serrao M, Rossi P, Valente G, Fattapposta F, Pierelli F, Amabile G (2000) A perdischarge activity in neuropathic patients with frequent muscle cramps. Acta Neurol Scand 102(6):359–362

    Article  CAS  Google Scholar 

  9. Roeleveld K, van Engelen BG, Stegeman DF (2000) Possible mechanisms of muscle cramp from temporal and spatial surface EMG characteristics. J Appl Physiol 88(5):1698–1706

    Article  CAS  Google Scholar 

  10. Fermont J, Arts IM, Overeem S, Kleine BU, Schelhaas HJ, Zwarts MJ (2010) Prevalence and distribution of fasciculations in healthy adults: effect of age, caffeine consumption and exercise. Amyotroph Lateral Scler 11(1–2):181–186

    Article  CAS  Google Scholar 

  11. Czell D, Goldman B, Weber M (2016) Distribution of fasciculations in healthy adults after exercise: an ultrasound study. Muscle Nerve 54(1):132–135

    Article  Google Scholar 

  12. Caress JB, Walker FO (2002) The spectrum of ectopic motor nerve behavior: from fasciculations to neuromyotonia. Neurologist 8(1):41–46

    Article  Google Scholar 

  13. Bertolasi L, De Grandis D, Bongiovanni LG, Zanette GP, Gasperini M (1993) The influence of muscular lengthening on cramps. Ann Neurol 33(2):176–180

    Article  CAS  Google Scholar 

  14. Denny-Brown D (1953) Clinical problems in neuromuscular physiology. Am J Med 15:368–390

    Article  CAS  Google Scholar 

  15. Baldissera F, Cavallari P, Dworzak F (1994) Motor neuron ‘bistability’. A pathogenetic mechanism for cramps and myokymia. Brain 117(5):929–939

    Article  Google Scholar 

  16. Norris FH, Gasteiger EL, Chatfield PO (1957) An electromyographic study of induced and spontaneous muscle cramps. Electroencephalogr Clin Neurophysiol 9(1):139–147

    Article  Google Scholar 

  17. Ross BH, Thomas CK (1995) Human motor unit activity during induced muscle cramp. Brain 118(4):983–993

    Article  Google Scholar 

  18. Forshew DA, Bromberg MB (2003) A survey of clinicians’ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 4(4):258–263

    Article  Google Scholar 

  19. Weber M, Goldman B, Truniger S (2010) Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised,double-blind crossover trial. J Neurol Neurosurg Psychiatry 81(10):1135–1140

    Article  CAS  Google Scholar 

  20. Bedlack RS, Pastula DM, Hawes J, Heydt D (2009) Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 10(4):210–215

    Article  Google Scholar 

  21. Food, Drug Administration (2006) FDA orders unapproved quinine drugs from the market and cautions consumers about ‘oC-label’ use of quinine to treat leg cramps. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108799.htm. Zugegriffen: 9. Okt. 2019

  22. Food, Drug Administration (2010) New risk management plan and patient medication guide for Qualaquin (quinine sulfate). http://www.fda.gov/Drugs/DrugSafety/postmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm. Zugegriffen: 9. Okt. 2019

  23. Milovanović JR, Janković SM, Pejčić A, Milosavljević M, Opančina V, Radonjić V, Protrka Z, Kostić M (2017) Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother 18(13):1381–1389

    Article  Google Scholar 

  24. Davies SL, Moral MA (2006) Clinical development of levetiracetam for amyotrophic lateral sclerosis. Drug News Perspect 19(9):572–573

    CAS  PubMed  Google Scholar 

  25. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861–9866

    Article  CAS  Google Scholar 

  26. Bajjalieh SM, Peterson K, Linial M, Scheller RH (1993) Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci USA 90:2150–2154

    Article  CAS  Google Scholar 

  27. Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 14:5223–5235

    Article  CAS  Google Scholar 

  28. Crowder KM et al (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA 96:15268–15273

    Article  CAS  Google Scholar 

  29. Janz R, Goda Y, Geppert M, Missler M, Südhof TC (1999) SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release. Neuron 24:1003–1016

    Article  CAS  Google Scholar 

  30. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26:1303–1313

    Article  CAS  Google Scholar 

  31. Nowack A, Yao J, Custer KL, Bajjalieh SM (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol, Cell Physiol 299:C960–C967

    Article  CAS  Google Scholar 

  32. Restivo DA, Casabona A, Frittitta L, Belfiore A, Le Moli R, Gullo R, Vigneri R (2018) Efficacy of botulinum toxin A for treatingcramps in diabetic neuropathy. Ann Neurol 84(5):682–690

    Article  Google Scholar 

  33. Supakatisant C, Phupong V (2015) Oral magnesium for relief in pregnancy-induced leg cramps: a randomised controlled trial. Matern Child Nutr 11(2):139–145

    Article  Google Scholar 

  34. Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, Cudkowicz ME, Weiss M, Miller RG, McDonald CM (2018) Mexiletine for muscle cramps in ALS: a randomized doubleblind crossover trial. Muscle Nerve. https://doi.org/10.1002/mus.26117

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Neurology, Spital Linth, Uznach, Schweiz

    Katharina Kneppe &  David Czell

  2. Neurologen am Zürichsee, Spital Männedorf, Asylstraße 10, 8708, Männedorf, Schweiz

    David Czell

Authors
  1. Katharina Kneppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Czell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Czell.

Ethics declarations

Interessenkonflikt

K. Kneppe und D. Czell geben an, dass kein Interessenkonflikt besteht. Insbesondere besteht keine finanzielle Unterstützung vom Hersteller (UCB-Pharma SA).

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kneppe, K., Czell, D. Brivaracetam – eine gute Alternative zur Behandlung von Muskelkrämpfen. Nervenarzt 91, 1130–1133 (2020). https://doi.org/10.1007/s00115-020-01001-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-020-01001-z

Schlüsselwörter

Keywords

Search

Navigation